Skip to Content
You are currently on the new version of our website. Access the old version .
  • Review
  • Open Access

26 May 2021

21 Pages

Old and New Challenges in Uveitis Associated with Behçet’s Disease

,
,
and
1
Department of Ophthalmology, Hôpital Charles Nicolle, F-76000 Rouen, France
2
Department of Internal Medicine, Hôpital Charles Nicolle, F-76000 Rouen, France
3
Department of Internal Medicine and Clinical Immunology, AP-HP, Centre National de Références Maladies Autoimmunes et Systémiques Rares et Maladies Autoinflammatoires Rares, Groupe Hospitalier Pitié-Salpêtrière, F-75013 Paris, France
4
Sorbonne Universités, UPMC Univ Paris 06, INSERM, UMR S 959, Immunology-Immunopathology-Immunotherapy (I3), F-75005 Paris, France

Abstract

Behçet’s disease (BD) is a systemic vasculitis disease of unknown origin occurring in young people, which can be venous, arterial or both, classically occlusive. Ocular involvement is particularly frequent and severe; vascular occlusion secondary to retinal vasculitis may lead to rapid and severe loss of vision. Biologics have transformed the management of intraocular inflammation. However, the diagnosis of BD is still a major challenge. In the absence of a reliable biological marker, diagnosis is based on clinical diagnostic criteria and may be delayed after the appearance of the onset sign. However, therapeutic management of BD needs to be introduced early in order to control inflammation, to preserve visual function and to limit irreversible structural damage. The aim of this review is to provide current data on how innovations in clinical evaluation, investigations and treatments were able to improve the prognosis of uveitis associated with BD.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.